In patients who received previous sequential chemoradiotherapy , overall survival did not differ between the 291 ( 35 % ) patients in the tecemotide group and the 142 ( 35 % ) patients in the placebo group ( 19.4 months [ 95 % CI 17.6-23 .1 ] vs 24.6 months [ 18.8-33 .0 ] , respectively ; adjusted HR 1.12 , 0.87-1 .44 ; p = 0.38 ) .